Literature DB >> 14758775

Natalizumab. Elan/Biogen.

Mariano J Elices1.   

Abstract

Natalizumab is a humanized monoclonal antibody to alpha 4 beta 1 integrin (VLA-4) currently under development by Elan and Biogen for the treatment of Crohn's disease and multiple sclerosis. Phase II trials in both indications have been completed, and by December 2002 phase III trials in Crohn's disease and multiple sclerosis had been initiated.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14758775

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  3 in total

1.  Presence and expression of JCV early gene large T Antigen in the brains of immunocompromised and immunocompetent individuals.

Authors:  Serena Delbue; Emanuela Branchetti; Renzo Boldorini; Luca Vago; Pietro Zerbi; Claudia Veggiani; Sara Tremolada; Pasquale Ferrante
Journal:  J Med Virol       Date:  2008-12       Impact factor: 2.327

Review 2.  [Blocking adhesion molecules with natalizumab in multiple sclerosis].

Authors:  B Schreiner; B C Kieseier; H-P Hartung; R Hohlfeld; H Wiendl
Journal:  Nervenarzt       Date:  2005-08       Impact factor: 1.214

Review 3.  Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action.

Authors:  Kavitha Damal; Emily Stoker; John F Foley
Journal:  Biologics       Date:  2013-11-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.